Phase 3 N=30 Ambrisentan in Patients With Porto-pulmonary Hypertension A Multicenter Open Label Trial
Portopulmonary Hypertension
Primary: Change in Pulmonary Vascular Resistance — 7.1 percent difference from baseline
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=85 PORtopulmonary Hypertension Treatment wIth maCitentan - a randOmized Clinical Trial
Portopulmonary Hypertension
Primary: Relative Change From Baseline to Week 12 in Pulmonary Vascular Resistance (PVR). — 0.63; 0.98 ratio — p=0.0001
N/A N=13 A Study to Assess the Safety and Efficacy of Treprostinil to Facilitate Liver Transplantation in Patients With Portopulmonary Hypertension
Portopulmonary Hypertension · Pulmonary Arterial Hypertension · Pulmonary Hypertension
Primary: Number of Subjects Who Achieved Hemodynamic Parameters Appropriate for Orthotopic Liver Transplantation Candidacy at Week 24. — 1; 12 participants
Phase 4 N=5 Management of Acute Pulmonary Hypertensive Crisis in Children With Known Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension
Primary: Change in Systemic Vascular Resistance Index (SVRI) to Pulmonary Vascular Resistance Index (PVRI) Ratio (Rp:Rs Ratio) — 0.8; 0.75; 0.61; 0.73 Rp:Rs ratio — p=0.9
N/A N=246 Assessing Portal Hypertension With Methacetin Breath Test
Patients With Compensated Liver Cirrhosis
Primary: CSPH (Clinically Significant Portal Hypertension) — 81.82 percentage of agreement
N/A N=30 PAHTCH Pulmonary Arterial Hypertension Treatment With Carvedilol for Heart Failure (Carvedilol)
Pulmonary Hypertension
Primary: Cardiac Glucose Uptake in FDG-PET (Fluorodeoxyglucose-Positron Emission Tomography) — 1.0; 0.6; 0.9; 0.8 standardized uptake value (SUV) — p=0.04
Phase 4 N=178 Noninvasive Subharmonic Aided Pressure Estimation of Portal Hypertension
Liver Diseases · Portal Hypertension
Primary: Diagnostic Accuracy of SHAPE Liver Pressure Estimates (in dB) for Diagnosing Portal Hypertension With Catheter Pressure Measurements (in mmHg) as the Reference Standard…
N/A N=21 Auto-PAP for Pulmonary Hypertension Treatment in Decompensated HF Patients With Sleep Apnea.
Sleep Apnea, Obstructive · Hypertension, Pulmonary · Heart Failure
Primary: Pulmonary Artery Systolic Pressure. — 58.6; 62.7; 42.8; 57.5 mmHg
Phase 2 N=36 Tadalafil for Pulmonary Hypertension Due to Chronic Lung Disease
Pulmonary Hypertension · Chronic Obstructive Pulmonary Disease (COPD)
Primary: Change in 6 Minute Walk Test — 7.00; 16.60; 16.00; 4.90 Meters walked in 6 minutes
Phase 3 N=70 Iloprost Power 15 in Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension
Primary: 6-minute-walk Distance (6MWD) — 330.0; 328.6 meters — p=0.7883
N/A N=70 Velacur by Sonic Incytes for Portal Hypertension
Portal Hypertension · Chronic Advanced Liver Disease
Primary: Liver Stiffness Measurements for Participants With Compensated Advanced Chronic Liver Disease With and Without Esophageal Varices Upon Esophagogastroduodenoscopy (EGD)…
Phase 2 N=151 Selonsertib in Adults With Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension
Primary: Change From Baseline in Pulmonary Vascular Resistance (PVR) at Week 24, as Measured by Right Heart Catheterization (RHC) — 35; -28; -21; 6 dyne*sec/cm^5 — p== 0.214
Phase 4 N=19 Hypoxic Pulmonary Vasoconstriction Pilot Study
Emphysema
Primary: Perfused Blood Volume Assessed for a Change in Lung Inflammation Pre and Post Dose Sildenafil Administration — 0.37; 0.42 coefficient of variation — p=<0.05
Phase 2 N=23 A Study of IDN-6556 in Cirrhotic Subjects With Portal Hypertension
Liver Cirrhosis · Hepatic Cirrhosis · Portal Hypertension
Primary: Hepatic Venous Pressure Gradient (HVPG) — 15.2; 8.05; 20.62; 14.1 mmHg — p=0.257
N/A N=455 The Association With Peptic Ulcer Disease and Hepatic Vein Pressure Gradient
Cirrhosis · Chronic Liver Disease
Primary: The Association of HVPG and PUD in Patients With Liver Cirrhosis — 14.5; 15.3 mmHg
N/A N=25 Catheter Placement for Hepatic Hydrothorax
Pleural Effusion
Primary: Feasibility of Using Indwelling Tunneled Pleural Catheters for the Management of Hepatic Hydrothorax — 25 Participants
Phase 2 N=10 The Effect of Sorafenib on Portal Pressure
Clinically Significant Portal Hypertension
Primary: Patients With Change in HVPG From Baseline — 1; 1 participants
Phase 3 N=151 Bosentan in Patients With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Pulmonary Hypertension
Primary: Change From Baseline to All Assessed Time Points in 6-minute Walk Test (6MWT) Distance — 8.4; 18.2; 17.7; 20.2 walk distance change from baseline (m)
N/A N=103 Assessmet of Patients With PAH Right Ventricular Volume
Pulmonary Arterial Hypertension
Primary: Observed Mean (Std Err) for % Difference Between VMS and MRI. — 4.80; 1.76; 2.03 Percent difference
Phase 2 N=57 Clinical Study to Assess the Efficacy and Safety of Macitentan in Patients With Pulmonary Hypertension After Left Ventricular Assist Device Implantation
Pulmonary Hypertension
Primary: Pulmonary Vascular Resistance (PVR) Ratio of Week 12 to Baseline — 0.585; 0.757 Ratio — p=0.0158
Phase 1 N=9 Frespaciguat (MK-5475) in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD) (MK-5475-006)
Pulmonary Hypertension
Primary: Percentage of Participants Who Experienced at Least 1 Adverse Event (AE) — 33.3; 33.3; 33.3; 80.0 Percentage of Participants
Phase 2 N=30 Study to Assess Safety and Efficacy of Ifetroban for Treatment of Portal Hypertension in Cirrhotic Patients
Portal Hypertension · Liver Cirrhosis
Primary: Safety (Incidence and Severity of Adverse Events) — 23; 2 Number of adverse events
Phase 2 N=15 Treprostinil Therapy For Patients With Interstitial Lung Disease And Severe Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension · Interstitial Lung Disease · Idiopathic Pulmonary Fibrosis
Primary: 6 Minute Walk Distance — 230 meters
N/A N=8 Bosentan and Pulmonary Endothelial Function
Pulmonary Arterial Hypertension
Primary: Acetylcholine Vascular Reactivity Response — 180 percentage of baseline
Phase 1 N=23 Single Dose Study in Patients With Chronic Obstructive Pulmonary Disease (COPD) Associated Pulmonary Hypertension.
Hypertension, Pulmonary · Pulmonary Disease, Chronic Obstructive
Primary: Swan-Ganz Hemodynamics - Maximal Change From Baseline at Day 1 of Mean Pulmonary Artery Pressure (PAPmean) — -3.60; -4.83 mmHg
Phase 4 N=37 BREATHE 5-OL: Tracleer (Bosentan) in Patients With Pulmonary Arterial Hypertension Related to Eisenmenger Physiology
Pulmonary Arterial Hypertension
Primary: Change in 6-minute Walk Distance — 13.5 m
Phase 2 N=35 Oral Pirfenidone for the Pulmonary Fibrosis of Hermansky-Pudlak Syndrome
Albinism · Inborn Errors of Metabolism · Oculocutaneous Albinism
Primary: Change in Forced Vital Capacity (36 Months) — -23.52; -20.93 % of predicted volume
Phase 2 N=16 Ambrisentan in Single Ventricle
Hypoplastic Left Heart Syndrome · Hypoplastic Right-sided Heart Complex
Primary: Area Under the Curve for Ambrisentan Plasma Concentration — 7871.46 ng*hr/mL
Phase 2 N=36 Phase 2 Study of Ambrisentan for Liver Function Test Rescue in Pulmonary Arterial Hypertension
Pulmonary Hypertension
Primary: The Incidence of Confirmed Serum Alanine Aminotransferase (ALT) or Aspartate Aminotransferase (AST) Concentrations > 3 x the Upper Limit of Normal (ULN) Considered to be…
N/A N=81 COMPASSION - COngenital Multicenter Trial of Pulmonic VAlve Regurgitation Studying the SAPIEN InterventIONal THV
Pulmonary Valve Insufficiency · Pulmonary Regurgitation · Dysfunctional RVOT Conduit
Primary: Freedom From Device or Procedure Related Death or Reintervention — 97.1 percentage of participants